Expecting more for your patients with IgAN1-5
Each year, patients with IgA Nephropathy (IgAN) experience an average eGFR decline of approximately 5 mL/min/year, and while supportive treatments alone fail to target IgAN at its source.5
Elevating the standard of patient care in IgAN6
Growing evidence suggests stringent treatment goals for IgAN including the fundamental treatment goal of minimizing eGFR loss to <1 mL/min/year, and highlights prevention or reduction of IgA immune complex formation via reduction in Gd-IgA1 as a first-line treatment goal. Most patients are not achieving recommended proteinuria and eGFR goals, leaving them at a substantial lifetime risk of end-stage kidney disease (ESKD).3,7
The data now supports the importance of more stringent goals for proteinuria and eGFR decline7,8
Proteinuria should now
be reduced to
<0.5 g/d or less
Loss of kidney function as measured by eGFR should now be reduced to
<1 mL/min/year
No supportive treatments for IgAN have been shown to consistently reduce eGFR decline to <1 mL/min/year or reduce proteinuria to <0.5 g/d or less across a broad patient population, suggesting the need for disease-modifying therapy to meet emerging standards.3,7
New IgAN treatment goals highlight the need to target the immunologic source of IgAN6,8
BAFF and APRIL both independently support B-cell overactivation, fueling the upstream immune upregulation that leads to Gd-IgA1 production and kidney-damaging immune complexes in IgAN.3
All individuals in the posted videos have been compensated by Vera Therapeutics for their time.
Watch Dr Tumlin discuss the role of BAFF and APRIL in the above video and explore more expert-led videos here.
Dual inhibition of BAFF and APRIL may help mitigate disease activity by reducing immune complex formation and preserving nephrons.3
Discover the latest peer-reviewed research and clinical tools
Find the latest research and publications on IgAN, including the role of BAFF and APRIL.
Test your IgAN IQ
Answer these 5 questions to test your knowledge of IgAN progression, pathophysiology, latest treatment goals, and more.
For informational purposes only and not a substitute for professional medical training or education.
Test your IgAN IQ
Question 1 of 5
Approximately what percentage of adult patients with IgAN develop kidney failure or die within 20 years of diagnosis?
Correct!
Approximately 75% of adult patients with IgAN develop kidney failure or die within 20 years of diagnosis.
A retrospective cohort study of patients with IgAN showed that even patients who are "low risk" are likely to experience kidney failure in their lifetime.1
Incorrect
Approximately 75% of adult patients with IgAN develop kidney failure or die within 20 years of diagnosis.
A retrospective cohort study of patients with IgAN showed that even "low risk" patients are likely to experience kidney failure in their lifetime.1
Thank you for completing the IgAN quiz! You correctly answered [X]/5!
Sign up to stay informed and keep learning about the latest news and advancements in IgAN.
Keep up with the latest advancements in IgAN
Sign up to receive emails on all the latest IgAN insights, news, and research from Vera Therapeutics. These updates are intended for US healthcare professionals only.
References: 1. Mathur M, Barratt J, Chacko B, et al; ENVISION Trial Investigators Group. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20-31. doi:10.1056/NEJMoa2305635 2. Lafayette R, Kristensen J, Stone A, et al; NefIgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859-870. doi:10.1016/S0140-6736(23)01554-4. Erratum in: Lancet. 2023;402(10405):850. doi:10.1016/S0140-6736(23)01851-2 3. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. doi:10.3389/fneph.2023.1346769 4. Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36-45. doi:10.36469/001c.26129 5.Data on File. Vera Therapeutics. 6. Barratt J, Lafayette RA, Floege J. Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne). 2024;11:1461879. doi:10.3389/fmed.2024.1461879 7. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135 8. Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107(4):640-651. doi:10.1016/j.kint.2025.01.014